



NEWSLINE

A PUBLICATION OF THE COLLEGE ON PROBLEMS OF DRUG DEPENDENCE, INC.

Volume Eighteen, Number Two • March 2014

CPDD President's Column

FRANK J. VOCCI, PH.D.
PRESIDENT

I hope everyone had a great holiday season and is doing well in this tough winter. I have some updates that turned out to be better news than we were expecting. Although we were expecting a slight decrease, the NIH actually got a budget increase, effectively ending the budget sequester. NIDA got a 3.31% increase from \$992 million to \$1.025 billion for the fiscal year. Although the increase did not restore NIDA's budget to pre-sequestration levels, more grants can be funded and the pay line will not be so tight. The leadership of CPDD will continue to lobby for increased research funding. We have met, and will continue to meet, with the staffs of prominent Senate and House Congressional offices to ensure they are aware of the value of medical research and the need for continued support of the medical research enterprise. You should know that you can meet with the Congressional representative in your state to emphasize the same messages to them. It's your right as a taxpayer and your duty as a scientist.

As you are all aware, Dr. Francis Collins, the NIH Director, decided to have a functional integration of NIDA and NIAAA. Expect to see joint program announcements and joint RFAs to be co-funded by the

two institutes. The functional integration decision also gave Dr. Collins the opportunity to select Dr. George Koob as the new NIAAA director. George is an internationally renowned neuroscientist who easily bridges pre-clinical and clinical science, making him an outstanding choice for the directorship of NIAAA. George is also a colleague and friend who deserves our support for his tenure at the head of NIAAA. I have invited George to speak at the annual meeting in San Juan about his priorities for NIAAA research for the next several years. Another reason that George is an outstanding choice for NIAAA is that he and Nora Volkow have a longstanding collegial relationship that should facilitate the functional integration of the two institutes.

Annual meeting

The Program Committee, headed by Dr. Elise Weerts, has completed its selections of symposia and workshops for the 2014 meeting. I would like to thank them for all their hard work in selecting the "best of the best" proposals. I would also like to take this opportunity to announce that Dr. Andy Coop will give the President's lecture on Sunday June 15. The title of his presentation is: "The Harrison Act at 100. Past, present, and future science behind the search

Continued on page 2

President's Column *continued from page 1*

for new opioid analgesics". The Harrison Act of 1914 forbids the prescribing of opioids for the management of opioid dependence. At that time there was also the perception that a legal and sociological approach was inadequate to address the myriad problems of opioid dependence. One offshoot of this perception was that the problem would be greatly reduced if safer, non-addicting opioid analgesics could be developed. As many of you know the Committee on Problems of Drug Dependence, our predecessor organization, sprang forth from this perceived need. Dr. Coop will cover 100 years of the search and the future directions that present themselves from current research findings. I encourage you to attend to get a perspective on analgesic medication development and the problem of opioid dependence in the US today.

Future meetings

CPDD has partnered with several organizations over the years, with those groups sponsoring meetings that are coordinated with our annual meeting. NIDA's International Program and the International Study Group Investigating Drugs as Reinforcers (ISGIDAR) regularly hold satellite meetings with CPDD, and the International Narcotics Research Conference (INRC) and Australasian Professional Society on Alcohol and other Drugs (APSAD) have had joint meetings with us in recent years. These have generally been successful, and we have been working on overlap meetings with other scientific societies. We will be holding a joint meeting with the INRC in Phoenix in 2015, and the Research Society on Alcoholism (RSA) in San Diego in 2018. We plan to schedule meetings with the International Cannabinoid Research Society (ICRS), the Society for Prevention Research, Society for Neuroimmune Pharmacology, and the National Hispanic Science Network (NHSN) on Drug Abuse, and remain open to partnering with other organizations as well.

I hope to see you in San Juan in June.

Important Information: 2014 Meeting

Location

Caribe Hilton, San Juan, Puerto Rico

Dates

June 14-19, 2014

Deadline for Early Registration Rates

April 13, 2014

Deadline to Request Refund

May 31, 2014

Late Breaking Research Submission Deadline

April 15, 2014

Late-Breaking Research Guidelines Link

http://www.cpdd.vcu.edu/Pages/Links/Links_PDFs/2014LateBreakingResearch.pdf

Meeting Registration Link

<https://www.regonline.com/Register/Cheekin.aspx?EventID=1333139>

Hotel Reservation Link

https://resweb.passkey.com/Resweb.do?mode=welcome_ei_new&eventID=10816818

Exhibitor Information Link

http://www.cpdd.vcu.edu/Pages/Links/Links_PDFs/2014exhibapplanrules.pdf

CPDD Conflict of Interest Information Link

http://www.cpdd.vcu.edu/Pages/Index/Index_PDFs/COI_Policy_CPDD.pdf

2013 AWARD WINNERS

The Introductory Remarks and Recipient Comments are continued from the previous issue of Newsline.

CPDD/NIDA Media Award: David Sheff

Introduction by Marc Kaufman

The Media Award is presented to individuals who have made major contributions to the public understanding of scientific and other issues concerning drug use disorders.

On behalf of the CPDD Media Relations Committee, I'm very pleased to have presented the CPDD/NIDA Media Award to Mr. David Sheff, author of the books "Beautiful Boy: a Father's Journey Through His Son's Addiction", and "Clean: Overcoming Addiction and Ending America's Greatest Tragedy".

David's book "Beautiful Boy", a New York Times #1 Bestseller in 2008, described his personal struggle with his son Nic's addiction, subsequent treatment, partial recovery, and relapse. The book led to David's being named Time Magazine's Time 100 in 2009, as one of the scientists and thinkers who most affect our world. This is just one of many awards he has won for his work.

David's new book, "Clean", follows up on Nic's struggle by exploring in depth the science underlying addiction disorders and the dysfunction in our addiction treatment system, which results in tragically high relapse rates. Accordingly, David's body of work captures the spirit of the CPDD/NIDA Media Award by making great strides toward increasing the public's understanding of the scientific basis of drug use disorders. It seems especially appropriate the award was presented on Father's Day, as we celebrated all fathers, and acknowledged David's efforts to write books about addiction, which in my opinion, epitomize the concept of fatherly love.

Comments by David Sheff

It's a great honor to have been at CPDD with those who are defining this field and creating its future. Many people there helped educate me about this disease—what we know, what we don't know, and the implications for prevention and treatment and policy. In particular I'd like to thank Nora Volkow, Tom McLellan, Rick Rawson, Steve Shoptaw, Marv Seppala, and the many NIDA researchers who generously granted their time and shared their expertise. I learned from many of you here in this room and was inspired by your devotion and compassion.

The first stage of my research for Clean wasn't difficult; it was easy to learn about the scope of the problem -- the 20 million people who are addicted, the 100 million family members who are affected. And the deaths --the 350 who die every day. I also learned about the healthcare, criminal justice, and lost productivity costs, and about other tragedies born in the places where addiction intersects with health



David Sheff (right) receives the 2013 CPDD/NIDA Media Award with introduction by Marc Kaufman (center). Also shown is CPDD past-president Richard De La Garza (left)

Continued on page 4

Award Winners continued from page 3

and societal problems -- poverty, violence, suicide, spousal and child abuse; all of the broken families, the broken neighborhoods -- and the addiction cycle that perpetuates.

The hardest to bear were the lessons I learned about the people behind the numbers. Every day, I hear from them and I often meet them -- devastated people suffering from their own or a loved one's addiction. Theirs is suffering that's beyond measure or description. Only if you've been there can you know. Too, too often parents or other loved ones approach me and I can see it in their eyes before they say a word. They show me photographs of their beautiful children. "He was the light of my life." "She was my angel." Child after child who is dead because they were afflicted with this disease and never got the treatment they needed.

So it wasn't hard to learn about the devastation. And if that's all I found, I'd be left with sad resignation.

But amid the pain; the devastation; the darkness, I found light -- light in the offices in which you treat sufferers of this disease and counsel their families; light in your needle exchange programs and methadone clinics; light in your laboratories and research sites where you are developing and testing new prevention and treatment strategies; and though, unfortunately, they were few and far between. I found light in programs where patients are treated by qualified practitioners who use evidence-based treatment. That is, I found light that comes from all of you who are devoted to preventing and treating this disease.

So on one hand, there is overwhelming wreckage.

But on the other, there's hope.

The challenge we now face is to bring them together. Because of your work, effective treatments are available and improving, but they must be made available to all people who need them. There's reason to be hopeful that this will happen. Finally. Tom McLellan pointed out that next year is the 100th anniversary of the Harrison Act when addiction was taken out of the hands of physicians -- and put in the hands of the criminal justice system. This shift contributed to a climate in which addiction has been treated as a problem of morals and character. But now there is a confluence of forces that are bringing this disease back to where it belongs so it will be faced for what it is. Not as a criminal or moral problem, but a health problem -- a healthcare crisis.

There's a slow but steady shift in Americans' understanding that addiction is a disease. Prejudice is pervasive, but it's waning as more people are educated. A major shift will begin next year when Obamacare kicks in. The hope of the Affordable Care Act -- at least its promise -- is that insurance will fully cover addiction treatment. When it does, presumably insurance plans won't pay for programs that blame addicts and punish them and demand their contrition. There will be accountability. Programs will either adapt and offer evidence-based treatment practiced by qualified professionals -- or they'll go out of business.

There's hope for prevention, too. From NIDA prevention specialists, I learned about the new paradigm for prevention that acknowledges that we will lower drug use and addiction rates when we focus our efforts less on drugs themselves, and more on why people use them. We'll better prevent drug use and addiction when we learn to better help our children grow up safely and healthily -- physically, emotionally, and psychologically; when we learn to identify

Continued on page 5

Award Winners continued from page 4

their risk factors and mitigate them—when we intervene as early as we can.

There’s yet another reason to be hopeful, and that’s a growing grassroots movement, a public outcry by people affected by addiction.

I’m from San Francisco, and in the 1980s I watched as the AIDS epidemic swept through our city. Two of my closest friends died. Very quickly there emerged a sense of urgency in the community. It led to a movement of people who declared that they would not tolerate the status quo. They mounted a campaign based on an understanding of the fact that SILENCE EQUALS DEATH.

SILENCE EQUALS DEATH when it comes to addiction, too. People are tired of the silence. They will no longer tolerate it. They are refusing to hide in the shadows. They are organizing in communities and around the nation -- circulating petitions, lobbying their legislators. For one example, grassroots organizations in several states, each started by parents who’ve lost their children to drugs, have succeeded in pushing through legislation for Good Samaritan laws. Now they’re working in other states and on other initiatives--such as making Narcan widely available and funding local treatment facilities for the poor. People around the nation are educating their communities when a new threat strikes—an epidemic of ODs on Xanax and heroin, for example; a flood of kids getting sick because of synthetic marijuana or the combination of prescription medications and cough syrup; or where a growing number of children in their community are dying of Oxycontin overdose. People are planning bikathons, teachathons, and a march on the Mall in Washington. They’re identifying candidates for office who commit to work with them to improve addiction prevention and treatment in their communities.

And finally, there’s one more reason I’m hopeful. And that reason is you. You in this room are on the front lines of this battle. You are our ultimate hope. You’re improving our ability to prevent this disease. You’re developing and putting into practice new life-saving treatments. Every day your

work is saving lives and as we go forward it will save more lives.

It wasn’t by choice that I became immersed in this field a decade ago. I was dragged in when my eldest son became addicted and was on a trajectory that was leading to his death. There was a time when I was certain that he wouldn’t make it to the age of 21. This year he turned 30 and celebrated his fifth year clean -- only because he finally underwent intensive treatment - evidence-based treatment developed and practiced by you and your colleagues. So my gratitude is boundless. You saved the life of my son just as you will save the lives of countless other of our sons and our daughters.

Thank you again for the great honor of receiving the CPDD/NIDA Media Award.

Joseph Cochin Young Investigator Award: William Stoops

Introduction by Craig Rush

It was my pleasure to introduce the recipient of the Cochin Young Investigator Award. In 2012, Dr. Tom Kelly introduced the recipient of this prestigious award, Dr. Joshua Lile, from the University of Kentucky. This year’s recipient, Dr. William Stoops, also calls the University of Kentucky home. Forgive the sports analogy, but only once in the storied history of our Men’s Basketball program has the University of Kentucky successfully defended the National Championship. The equally storied history of drug abuse research at the University of Kentucky has now defended a National Championship and is officially and deservedly on par with our Men’s Basketball program.

Dr. Stoops came to the University of Kentucky in 2000 after having completed his undergraduate degree at Davidson College in North Carolina under the advisement of Dr. Mark Smith. During his first semester of graduate school, Bill was not

Continued on page 6

Award Winners *continued from page 5*

William Stoops (center) receives the 2013 Joseph Cochin Young Investigator Award with introduction by Craig Rush (right)

quite sure with whom he wanted to work and completed lab rotations with me, Dr. Mark Fillmore and Dr. Tom Kelly. At the end of the semester, Bill informed me that he would like to finish his graduate work in my lab: What a fortunate decision -- FOR ME.

Dr. Stoops completed his graduate work in 2005 and went on to post-doctoral training in my lab and that of Dr. Sharon Walsh. Dr. Stoops joined the faculty at the University of Kentucky as a Research Assistant Professor in 2007 and was moved to a tenure track line in 2009. Just a few weeks ago Dr. Stoops received news that he had been granted tenure and promoted to Associate Professor. In a conversation in my office I told Dr. Stoops it could be hard to ever have a better year professionally than this past year - Tenure, Promotion, and the Young Investigator Award from CPDD.

The professional accomplishments of Dr. Stoops are too numerous to list. He received nearly every graduate student award and fellowship that was available at the University of Kentucky. He has received national awards including the Young Psychopharmacologist Award from Division 28 of the American Psychological Association. He has published nearly 80 peer-reviewed manuscripts and book chapters, and has enjoyed continuous R-level funding since joining the faculty. He is an accomplished teacher and mentor. This level of productivity is simply extraordinary given that last night we celebrated only his 35th birthday.

I am proud to introduce to you my student, my colleague and my friend, Dr. William W. Stoops, this year's recipient of the Cochin Young Investigator Award.

Comments by William Stoops

Several years ago, I was at an awards presentation and the awardee made the astute observation that a large portion of individual success originates in the environment, particularly the surrounding people and the workplace. I could not agree more and count myself very fortunate on both those accounts. In that spirit, I want to make a few important acknowledgements. First and foremost, thank you to my nominator, Dr. Craig R. Rush. You have been a generous, unwavering advocate, mentor and coach and I would not have made it to this point in my career without you. Second, I need to thank Dr. Sharon L. Walsh and Dr. Sandra D. Comer for writing letters of support for this award. Thank you, Sharon, for helping to expand my research interests as a postdoctoral fellow and for continued guidance as my career has progressed. Thank you, Sandy, for being an outstanding role model and for providing numerous opportunities to grow as a researcher.

I would also like to acknowledge Dr. Mark A. Smith and Dr. Joshua A. Lile. Mark sparked my interest in behavioral pharmacology during my junior year at Davidson College and set me on this path. Josh joined Craig's lab as a post-doc while I was a graduate student and I do not think I have ever learned so much or been as productive as the years the three of us were working under the same

Award Winners *continued from page 6*

roof. Both Mark and Josh remain invaluable colleagues and good friends, so, thanks to both of you.

I would be remiss if I did not thank our incredible team at the Laboratory of Human Behavioral Pharmacology, particularly Fran Wagner, for their hard work and dedication. Thank you to the faculty and staff of the Departments of Behavioral Science and Psychology at the University of Kentucky. Your collegiality and encouragement affirm my commitment to the important and challenging work we all do every day.

Thank you to the College on Problems of Drug Dependence and the Awards Committee for this honor. CPDD has been my “home” scientific organization for 13 years and I am grateful for its commitment to fostering young investigators, especially in a time when the challenges facing junior researchers are leading many to seek careers outside of science. Thank you, also, to the National Institute on Drug Abuse and National Cancer Institute for generous and vital research funding.

Lastly, I need to thank my mom, brother, other family and friends for their love and support.

Thanks again for this tremendous honor.

Mentorship Award: James Sorensen

Introduction by Howard Newville

It’s my honor to introduce Jim Sorensen, the 2013 winner of the CPDD mentorship award. I met Jim at CPDD’s annual meeting in 2008. I was a graduate student and made it my goal to approach as many researchers as I could. After I asked Jim about his study, he asked me about my training and my interests. I saw him again at CPDD the next year, and he remembered me. By that point I decided to prioritize UCSF in my internship search so that I could benefit from his mentorship.

I’ve seen the great pleasure he takes in mentoring others, whether they are interns, post-docs, or faculty members. He is the director of a T32 program funded by NIDA, the training director in our research center of excellence (P50), cluster leader of the Clinical Psychology Training Program for predoctoral and postdoctoral fellows, and co-director of a Visiting Professors Program at the Center for AIDS Prevention Studies (CAPS). He has trained 15 faculty members, 28 postdoctoral fellows, and 22 predoctoral fellows.

Those of us lucky to have worked with Jim understand Jim’s impact on the field goes beyond his research and to his trainees. His mentorship goes beyond the minimum effort required. He and his wife made the effort to help acclimate me to San Francisco by doing things like bringing me with them to their family barbecue for the Fourth of July back when I had just moved and knew nobody. His brilliant mentorship is the reason I got my F32. I am proud to call him my mentor and happy to present him with this award.

Comments by James Sorensen

Thank you so much, Dr. Howard Newville! This is a wonderful award, and I am thrilled to be chosen as the 2013 recipient. Thanks also to Suzette Evans and the Awards Committee of the College on Problems of Drug Dependence. When I learned of receiving this award, my immediate reaction was that it was a reflection of the wonderful mentees that I have been privileged to work with over the years.

My first mentee was a graduate student at Bowling Green State University, Joseph Galano. When he received a career achievement award from the American Psychological Association a few years ago, and I

Continued on page 8

Award Winners *continued from page 7*

realized that I was the mentor of this man who was getting an award for his career of accomplishments, then it came to me that the length of my footsteps behind me was probably longer than the footsteps in front of me would be. For those of you in CPDD who teach and provide guidance to others, you, too, may be an influential mentor before you know it! Over the years I have accumulated a debt of gratitude to the approximately 50 professionals I mentored, and I bask in the glow of their professional and personal lives and accomplishments.

My latest mentees to date have been a wonderful group, including Howard Newville, Jennifer Hetteema, Annesa Flentje, Jennifer Manuel, Sandra Larios & Danielle Ramo at University of California, San Francisco and Dr. Angela Chia Chen from Arizona State University. Several of them nominated me for the award. As I consider a former mentee, Carmen Masson, who was in attendance at CPDD, I am reminded of the special influence she has provided in the last 15 years since she came to UCSF as a postdoc and stayed as a faculty member. Every summer she mentors minority undergraduates from the Summer with NIDA Research Program for Underrepresented Populations, and she has given back much more than she ever took as a student. Thank you mentees!

My own development was a result of efforts from countless people who coached, inspired, and mentored me over the years, including Bill Hargreaves and Reese Jones at UCSF, and going back through graduate, undergraduate, secondary, and even elementary school, and of course my parents Les and Bev Sorensen and my spouse of 31 years, Laurel Koepernik.

CPDD has given this award since 2000, and I am proud to have known a number of the award winners---people that I looked up to and continue to do so, including Bob Balster, Bob Schuster, Jim Anthony, Scott Lukas, Chuck O'Brien, and Kathy Cunningham. When I was on the Board of CPDD I learned that a perennial complaint of members was the scheduling of the meeting....always on the 3rd Sunday of June, which as you probably know is

Father's Day. It seems especially appropriate to have given out a Mentorship Award on a day that honors parents, and I want to thank all of you for this special honor.



James Sorensen (center) receives the 2013 Mentorship Award with introduction by Howard Newville (right).

CPDD OFFICERS

- FRANK VOCCI, JR., PHD,
PRESIDENT
- RICHARD DE LA GARZA, II, PH.D.
PAST-PRESIDENT
- ERIC STRAIN, JR., M.D.,
PRESIDENT-ELECT
- THEODORE J. CICERO, PHD,
TREASURER
- MARTIN W. ADLER, PHD,
EXECUTIVE OFFICER

BOARD OF DIRECTORS

- MICHAEL T. BARDO, PHD
- ALAN J. BUDNEY, PHD
- ANDREW COOP, PHD
- LINDA B. COTTLER, PHD, MPH
- LINDA P. DWOSKIN, PHD
- LINDA A. DYKSTRA, PHD
- TOBY EISENSTEIN, PH.D.
- MARGARET HANEY, PH.D.
- CARL L. HART, PHD
- STEPHEN T. HIGGINS, PHD
- MARC J. KAUFMAN, PH.D.
- MARY JEANNE KREEK, MD
- A. THOMAS MCLELLAN, PHD
- GREGORY M. MILLER, PHD
- CHARLES O'KEEFFE, M.B.A.
- ROGER D. SPEALMAN, PHD

**AMY K. GOODWIN, PHD, EDITOR
CPDD PUBLICATIONS COMMITTEE**

- RAJEEV RAMCHAND, CHAIR
- MIKE TAFFE
- GEORGE UHL
- ERIC VALLENDAR
- JOHN MARSDEN
- SYLVIA MARTINS
- IAN STOLERMAN
- TAMMY CHUNG
- CECILE DENIS
- DRAKE MORGAN

Send materials for **NEWSLINE** to:

Amy K. Goodwin
National Center for Toxicological
Research
U.S. Food & Drug Administration
3900 NCTR Rd
Jefferson, AR 72079
Email: Amy.Goodwin@fda.hhs.gov

Notable Committee News

Membership Committee

Since the last issue of Newsline, a total of 36 new members were added and the status of 11 members was upgraded. CPDD members will be hearing from the Membership Committee again soon as they move into another membership campaign.

Education, Outreach and Public Policy Committee

The CPDD Education, Outreach, & Public Policy and Media committees are supporting a new workshop at the 2014 meeting, titled "Knowledge Translation in Addiction Sciences: Why and How to Share Research Knowledge Beyond the Academic Community." The workshop is organized and chaired by committee members Doris Payer and Marc Kaufman, and aims to raise awareness about knowledge translation (i.e., the pro-active dissemination of research knowledge to help close the "know-do gap"), and to encourage addiction scientists to adopt KT strategies in their research. Presentations will demonstrate how research knowledge can inform clinical implementation (Laurie Zawertailo, Dominique Morisano) and public policy (Jane Maxwell), and will describe media relations (Bertha Madras) and social media/non-traditional strategies for science communication (The DrugMonkey), as well as initiatives undertaken by CPDD itself (Marc Kaufman).